Raymond James raised the firm’s price target on Hinge Health (HNGE) to $70 from $55 and keeps an Outperform rating on the shares. Hinge Health delivered a strong Q1 beat driven by exceptional billings growth and better-than-expected lives and yields, leading to a substantial full-year revenue outlook increase, with continued upside potential supported by product innovation and expansion initiatives, while shares appear undervalued relative to its growth and free cash flow profile, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports